| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Shuttle Pharmaceuticals Holdings Inc. | Ropidoxuridine | Glioblastoma | Phase 2 | Ongoing | Oral | Oncology |
| SIGA Technologies Inc. | Tecovirimat - (STOMP) | Human Mpox Virus | Phase 3 | Data Released | Oral | Antiviral |
| SIGA Technologies Inc. | PALM 007 (Tecovirimat for Treatment of Monkeypox Virus) | Monkeypox (mpox) | Phase 2 | Data Released | Oral | Antiviral |
| Silence Therapeutics Plc | Zerlasiran (formerly SLN360) - (ALPACAR-360) | Cardiovascular diseases and Polycythemia vera | Phase 3 | Trial Planned | Subcutaneous | Hematology |
| Silence Therapeutics Plc | Divesiran (SLN124) - (SANRECO) | Polycythemia Vera | Phase 2 | Enrollment Conclusion | Subcutaneous | Hematology |
| Sinovac Biotech Ltd. | Multivalent vaccines | HFMD caused by both Enterovirus 71 (EV71) and Coxsackievirus 16 (CA16) | Phase 3 | Trial Planned | Injection | N/A |
| Sinovac Biotech Ltd. | Antibody SA55 Injection | COVID-19 | Phase 2 | Intravenous | COVID-19 | |
| Sionna Therapeutics Inc. | SION-719 - (PreciSION CF) | Cystic Fibrosis | Phase 2a | Ongoing | intravenous | Respiratory |